China Healthcare Weekly(July20)-WuXi AppTec 25H1, Sino Biopharm Acquire LaNova, United Lab Placement
WuXi AppTec’s 25H1 Profit Alert indicates 2025 result may beat expectation. Sino Biopharm's acquisition of LaNova show high cost...
961 Views
3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?
​3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...
394 Views
Sichuan Kelun-Biotech Biopharm (6990.HK) - Current High Valuation Is Not Secure
The market has high hopes for SKB264's clinical data on NSCLC/TNBC, which will impact Akeso's future expectations. Be cautious of share price...
567 Views
HSCEI Dec 2026 Index Rebalance Forecast
We expect Shenzhou to be deleted below rank 60 and Hua Hong Grace to fill its seat, while a mid-conviction WuXi Bio ADD would also see ZTO deleted.
42 Views
Primer: Akeso (9926 HK) - Jun 2026
Akeso is a leader in the development of innovative bispecific antibodies, with its core products, cadonilimab (PD-1/CTLA-4) and ivonescimab...
113 Views